HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

J. Biol. Chem., Vol. 275, Issue 29, 21797-21800, July 21, 2000

This Article Abstract Full Text (PDF) All Versions of this Article: 275/29/21797    most recent C000023200v1 Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Osthus, R. C. Articles by Dang, C. V. Search for Related Content PubMed PubMed Citation Articles by Osthus, R. C. Articles by Dang, C. V. Social Bookmarking                      What's this?

ACCELERATED PUBLICATION
Deregulation of Glucose Transporter 1 and Glycolytic Gene Expression by c-Myc^*

Rebecca C. Osthus, Hyunsuk Shim^§¶, Sunkyu Kim^§, Qing Li^§, Rahul Reddy^§, Mita Mukherjee, Yi Xu, Diane Wonsey, Linda A. Lee^§, and Chi V. Dang^§**

From the  Program in Human Genetics and Molecular Biology, ^§ Department of Medicine, and  Department of Pediatrics, The Johns Hopkins University School of Medicine, Baltimore, Maryland 21205

Received for publication, January 12, 2000, and in revised form, May 9, 2000

	ABSTRACT

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Unlike normal mammalian cells, which use oxygen to generate energy, cancer cells rely on glycolysis for energy and are therefore less dependent on oxygen. We previously observed that the c-Myc oncogenic transcription factor regulates lactate dehydrogenase A and induces lactate overproduction. We, therefore, sought to determine whether c-Myc controls other genes regulating glucose metabolism. In Rat1a fibroblasts and murine livers overexpressing c-Myc, the mRNA levels of the glucose transporter GLUT1, phosphoglucose isomerase, phosphofructokinase, glyceraldehyde-3-phosphate dehydrogenase, phosphoglycerate kinase, and enolase were elevated. c-Myc directly transactivates genes encoding GLUT1, phosphofructokinase, and enolase and increases glucose uptake in Rat1 fibroblasts. Nuclear run-on studies confirmed that the GLUT1 transcriptional rate is elevated by c-Myc. Our findings suggest that overexpression of the c-Myc oncoprotein deregulates glycolysis through the activation of several components of the glucose metabolic pathway.

	INTRODUCTION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

To form a three-dimensional multicellular spheroid mass, neoplastic cells alter their metabolism such that they are able to survive and grow in the hostile microenvironments created by the decreased blood flow found in tumor vasculature (1, 2). The most striking feature of tumor cells is the production of large amounts of lactic acid, which is due to the glycolytic conversion of glucose to lactic acid even in the presence of oxygen (3). This is often accompanied by an increased rate of glucose transport (4-6).

Glucose is a major regulator of gene transcription. In particular, it stimulates transcription of genes encoding glycolytic and lipogenic enzymes in adipocytes and hepatocytes through the carbohydrate response element (ChoRE),¹ a 5'-CACGTG-3' motif (7-11). The ChoRE is similar to the core binding site for the transcription factors USF2 (12), which is implicated in glucose metabolism, TFE3, and the hypoxia-inducible transcription factor (HIF). Hence, the ChoRE serves to integrate physiological signals through transcription factors to regulate glucose metabolism.

During tumor formation, adaptation to hypoxia may be mediated by the HIF-1 family of transcription factors, which induce angiogenesis and other metabolic changes. (2, 13, 14). It is notable that glucose transport and transporter mRNA are induced in cells transformed by ras or src oncogenes (5). The c-myc oncogene is activated in a variety of pathways that are important in controlling cell growth and tumorigenesis. (15-18). Intriguingly, the ChoRE sequence matches the core E-box (5'-CACGTG-3') binding site for c-Myc, which binds E-boxes of target genes to stimulate transcription (2, 18, 19). Previous work showed that c-Myc directly up-regulates the expression of the lactate dehydrogenase gene (LDH-A) (20), which is important in the transformed phenotype (anchorage-independent growth) of cells that overexpress c-Myc (20, 21). In addition to LDH-A, we report here the deregulation of GLUT 1 and several glycolytic genes by c-Myc.

	EXPERIMENTAL PROCEDURES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Cell Culture and Transfection-- Rat fibroblasts were cultured in 5% CO₂ at 37 °C in DMEM supplemented with 10% fetal bovine serum (FBS; Life Technologies, Inc.) and antibiotics. Rat1a and Myc-transformed Rat1a-Myc fibroblasts were as described previously (22). Human lymphoid cells were cultured in Iscove's modified Dulbecco's medium with 10% FBS and antibiotics. Cells lacking c-myc (HO15), heterozygous HET15, and parental lines (TGR) (a gift of John Sedivy, Brown University) were cultured in DMEM supplemented with 10% FBS and antibiotics (23). HO15 cells were transfected with either MLVmyc or MLV empty vectors (20) using Lipofectin (Life Technologies, Inc.) according to the manufacturer's protocol. The human GLUT1 cDNA (24) was kindly provided by Drs. M. Mueckler (Washington University, St. Louis, MO) and C. Heilig (The Johns Hopkins University, Baltimore, MD).

A Rat1 cell line expressing a fusion protein of c-Myc and the human estrogen receptor (MycER) (a gift of J. M. Bishop, University of California, San Francisco) was grown in DMEM with 10% FBS, penicillin, and streptomycin (25). Myc activity was induced when confluent MycER cells were treated with 0.25 µM 4-hydroxytamoxifen (4-HOTM; Research Biochemicals, Natrick, MA) for the times indicated as described (20, 26). To block protein synthesis, 10 µM cycloheximide (CHX) was added to the cells 30 min prior to 4-HOTM treatment.

Adenoviral in Vivo Gene Transfer-- Animal studies were approved by The Johns Hopkins University School of Medicine Animal Use and Care Committee. Adenoviral constructs (a gift from W. El-Deiry, University of Pennsylvania, Philadelphia, PA) containing either LacZ (Ad/LacZ) or c-myc (Ad/c-myc) coding sequence were as described (27). Two-month-old male BALB/c mice, weighing 20-25 g, were intravenously injected with 4 × 10⁹ plaque-forming units (pfu) of either Ad/LacZ or Ad/c-myc. Mice were then sacrificed by exposure to CO₂ on days 3, 4, and 5 after viral injection. Their livers were quickly removed and processed for RNAs or frozen in liquid nitrogen.

RNA Analysis-- Total RNA was isolated by guanidium thiocyanate lysis followed by cesium chloride centrifugation. 15-µg aliquots of RNA were used in Northern blot analysis (22). IMAGE Consortium cDNA clones (28) were obtained (Research Genetics, Inc.), and the inserts were isolated and ³²P-labeled by Random-Primer synthesis using a Random-PrimeII kit (Stratagene).

Nuclear Run-on Assays-- Nuclear run-on assays were performed as described (20, 29). Nuclei were isolated from nonadherent cells (2 × 10⁷) and incubated with buffered [³²P]UTP (500 µCi), and labeled RNAs were isolated after treatment with DNase, proteinase K incubation, and phenol-chloroform extraction. Labeled RNAs (1.2 × 10⁷ cpm) from either Rat1a-Myc or Rat1a cells were hybridized at 42 °C for 40 h with membrane slot-blotted with denatured glucose transporter 1 and vimentin cDNA fragments.

2-[³H]Deoxyglucose (2-DG) Uptake-- Uptake experiments were conducted on confluent Rat1a and MycER cells. Cells were treated with 0.25 µM 4-HOTM (Research Biochemicals, Natrick, MA) 1 h before 0.1 mM 2-DG with 10 nM [³H]2-DG (final concentration) were added. At the end of a 10-min incubation, cells were washed with ice-cold phosphate-buffered saline. Cells were than lysed by the addition of 2 ml of 10 mM NaOH containing 0.1% Triton X-100, and a 100-µl aliquot was assayed for ³H by liquid scintillation counting (30). The protein content was measured by the method of Bradford (31).

	RESULTS

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Myc Induces GLUT1 and Glycolytic Gene Expression in Myc-transformed Fibroblasts and in Hepatocytes in Vivo-- To identify genes whose expression is deregulated in the presence of increased ectopic c-Myc, c-Myc-transformed Rat1a cells were studied (Fig. 1A). Using this system of isogenic cell lines, GLUT1, phosphofructokinase (PFK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), phosphoglucose isomerase (GPI), phosphoglycerate mutase (PGM), and enolase showed elevated mRNA levels in c-Myc-transformed cells as compared with the nontransformed Rat1a cells. The expression levels of aldolase A, aldolase C, and triose-phosphate isomerase (TPI) were decreased, and the expression levels of hexokinase I, hexokinase II, and phosphoenolpyruvate carboxykinase were unchanged. Rat vimentin was used as a control (32).

View larger version (34K): [in this window] [in a new window]   Fig. 1.   A, Northern analysis of GLUT1 and glycolytic gene expression in nonadherent Rat1a-Myc (R1a-Myc) or Rat1a (R1a) fibroblasts. Vimentin served as a sample loading control. PEPCK, phosphoenolpyruvate carboxykinase; Ald, aldolase. B, c-Myc protein expression at 3-5 days after injection of adenovirus-expressing c-Myc. Equal amounts of protein (20 µg/lane) were loaded, and Western analysis was performed with the monoclonal anti-Myc 9E10 antibody. C, elevated in vivo glycolytic gene expression in c-myc adenovirally transduced murine livers. Numbers at the bottom represent days after injection of adenovirus-expressing galactosidase (LacZ) or c-Myc. 18 S rRNA is shown as a loading control.

To determine whether c-Myc could induce GLUT1 and glycolytic gene expression in vivo, we injected adenoviruses expressing either LacZ or c-Myc into mice. Tail-vein injection of adenoviruses has the advantage of very high hepatic clearance, which yields highly efficient gene delivery to the liver (33). Four days after injection, 40% of hepatocytes were positive for -galactosidase in LacZ adenovirus-treated animals (data not shown).² c-Myc protein levels were 10-fold elevated in Myc adenovirus-treated animals (Fig. 1B). GLUT1, PFK, GAPDH, PGM, and enolase mRNAs were significantly induced in the Myc-expressing livers as compared with LacZ-expressing livers at 4 and 5 days after injection of viruses (Fig. 1C). These observations suggest that transient expression of Myc in vivo induces hepatic expression of the same glycolytic genes that are induced in the Rat1a system.

Glycolytic Genes That Are Direct Targets of c-Myc-- To determine whether the genes displaying increased or decreased levels of mRNA expression are transcriptionally activated by Myc, we used a previously described Rat1 fibroblast line expressing a protein that fuses Myc to the estrogen receptor ligand binding domain (MycER). With exposure of cells expressing the MycER protein to estrogenic compounds such as 4-hydroxytamoxifen (4-HOTM), the ligand-bound MycER protein translocates to the nucleus. The MycER protein then activates target genes without requiring new intervening protein synthesis (26, 34). Hence, prior exposure of MycER cells to the protein synthesis inhibitor cycloheximide (CHX) would not block activation or repression of direct target genes by 4-HOTM. Activation of MycER by 4-HOTM caused induction of GLUT1, PFK, and enolase mRNAs in the presence of CHX at 2 and 4 h (Fig. 2A). Note that mRNA levels are diminished in the CHX + TM samples at the 6 h time point; this is likely due to decreased MycER protein (10% of 0 h level) with CHX treatment (data not shown). GAPDH, GPI, and PGM expression were not increased in the MycER system. Thus, GAPDH, GPI, and PGM do not meet this criterion for direct targets of c-Myc. Among the potentially down-regulated genes identified in Rat1a-Myc cells, only TPI mRNA moderately decreased in MycER cells exposed to 4-HOTM. However, a decrease in TPI mRNA was also seen with CHX treatment alone. The ribosomal phosphoprotein (36B4) mRNA level was shown to be unresponsive to estrogen and independent of cell cycle progression (35, 36) and was therefore used as a control. To account for experimental variation, a separate tamoxifen induction experiment was performed, and GLUT1 expression in MycER cells was determined (Fig. 2B). Following c-Myc induction, GLUT1 expression behaves in a manner that is consistent with a direct c-Myc target.

View larger version (44K): [in this window] [in a new window]   Fig. 2.   A, direct c-Myc targets determined by the use of the Myc-estrogen receptor ligand binding domain (MycER) hybrid protein system. Rat1 fibroblasts expressing the MycER protein were treated with CHX, HT, or both reagents (CHX + TM), and RNAs were collected at the times (h) indicated at the bottom of the figure. Northern blots were probed with labeled cDNAs of GLUT1 (GT1) or glycolytic genes indicated along the left sides of the panels of blots. Both 18 S rRNA and human ribosomal phosphoprotein 36B4 are shown as loading controls. Both GPI and TPI mRNAs are labile with CHX exposure. DHAP, dihydroxyacetone phosphate; FBP, fructose 1,6-bisphosphate. B, Northern analysis of GLUT1 expression in a separate induction experiment with MycER cells. The labels are similar to those of A. The top of the figure shows the relative increase in GLUT1 expression (normalized to the loading control 36B4) as a function of time. For the 4-h time point, an average over three experiments from two induction experiments yielded the following relative increase (from zero time point) in GLUT1 expression with standard errors: CHX, 1.3 ± 0.5; TM, 2.7 ± 0.3; CHX + TM, 2.2 ± 0.4. C, Northern analysis of enolase, GLUT1, and PFK expression in 4-hydroxytamoxifen (TM) or TM plus cycloheximide (CHX + TM)-treated Rat1a cells lacking the MycER protein. Numbers at the bottom represent time of exposure. 18 S rRNA is shown as a loading control.

To determine whether 4-HOTM itself may directly increase the expression of GLUT1, PFK, and enolase independent of the MycER protein, we treated Rat1a cells lacking MycER with 4-HOTM, with or without CHX, and performed Northern analysis. The mRNA levels of these genes were unchanged upon addition of 4-HOTM and cycloheximide in the absence of the MycER protein (Fig. 2C). Hence, the induction of enolase, GLUT1, and PFK expression in the Rat1a-MycER cells by 4-HOTM is dependent on MycER activity.

Expression of GLUT1 and Glycolytic Genes in Cells Lacking c-Myc-- To further authenticate GLUT1, PFK, and enolase as c-Myc targets, we sought to determine their expression in Rat1 fibroblasts lacking c-myc (Fig. 3). All three transcripts showed decreased levels in c-myc null cells as compared with wild type parental cells. The expression of PFK and enolase are elevated in c-myc null cells rescued by a constitutively overexpressed c-Myc (HO15-Myc) when compared with empty vector control transfected myc null cells (HO15-MLV). GLUT1 expression, however, was only slightly elevated in the c-Myc-overexpressing HO15 cells as compared with control MLV transfected cells, which display elevated GLUT1 as compared with the parental HO15 cells. Replicate experiments yielded similar results, in which the HO15-MLV cells have elevated expression of all three genes as compared with the HO15 parental cell line. The cause for this elevation in our control HO15-MLV cells is not known. Thus, in this genetically defined system Myc levels parallel the expression of these three target genes.

View larger version (51K): [in this window] [in a new window]   Fig. 3.   Expression of enolase, GLUT1, and PFK mRNAs in wild-type (TGR(WT)), heterozygous (HET15), or c-myc null (HO15) Rat1 fibroblasts. HO15-MLV represents RNAs from myc null cells transfected with the empty MLV-LTR expression vector, and HO15-Myc the null cells reconstituted with an MLV-LTR driven human c-Myc expression vector. Both 18 S rRNA and ribosomal phosphoprotein 36B4 were used as loading controls.

Among the three up-regulated genes, GLUT1 is most frequently implicated in tumorigenesis (35-38). We therefore chose to characterize GLUT1 further. Nuclear run-on experiments demonstrated an enhanced transcriptional rate of GLUT1 in Rat1a-Myc cells as compared with Rat1a fibroblasts (Fig. 4A). The nuclear run-on signals for enolase and PFK were low and insufficient for interpretation (not shown). These results, nevertheless, underscore the activation of GLUT1 by c-Myc at the transcriptional level.

View larger version (32K): [in this window] [in a new window]   Fig. 4.   A, nuclear run-on studies showing increased transcription of GLUT1 in Rat1a-Myc nuclei as compared with Rat1a nuclei. Vimentin was used as a control. B, Northern blot showing expression of GLUT1 mRNA in untransformed CB33 human lymphoblastoid cells as compared with those with elevated c-Myc expression: CB33 with ectopic c-Myc expression (CB33-Myc) and Burkitt's lymphoma cell lines Ramos and ST486. Phosphoprotein 36B4 and 18 S rRNA are shown as loading controls. Relative GLUT1 mRNA levels are: CB33, 1.0; CB33-Myc, 1.8; Ramos, 11.2; and ST486, 4.3.

We further sought to determine whether GLUT1 expression parallels that of c-myc in Burkitt's lymphoma cells that are characterized by c-myc gene activation by chromosomal translocation. Both c-Myc-transformed lymphoblastoid (CB33-Myc) and Burkitt's lymphoma cell lines, Ramos and ST486, have elevated c-Myc protein levels (20) that are associated with elevations of GLUT1 mRNA levels compared with the nontransformed lymphoblastoid CB33 cells (Fig. 4B). We thus observed a correlation between c-Myc expression and the endogenous levels of GLUT1 mRNA in these Myc-transformed human lymphoid cells.

Increased Glucose Uptake in Myc-transformed Cells-- To determine whether increased Myc activity influences glucose transport, [³H]2-DG uptake was studied in MycER Rat1 cells as well as Rat1a cells lacking the MycER system. 4-HOTM increased [³H]2-DG uptake in MycER cells, while it had no influence in Rat1a cells (Fig. 5).

View larger version (17K): [in this window] [in a new window]   Fig. 5.   c-Myc stimulates glucose uptake in Rat1 fibroblasts. Rat1a and Rat1-MycER cells were grown under control conditions (TM) or with 4-hydroxytamoxifen (+TM), which induces c-Myc activity. Relative glucose uptake (mean ± S.D. from triplicate experiments) was determined by measuring intracellular 2-[3H]deoxyglucose (see "Experimental Procedures" for details).

	DISCUSSION

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

Normal mammalian cells use oxygen to generate energy from glucose and other metabolites through oxidative phosphorylation. In conditions of oxygen deprivation, normal cells rely on glycolysis to generate energy by converting glucose to lactic acid. Neoplastic transformation, however, alters glucose metabolism with enhanced conversion of glucose to lactic acid, thereby making tumor cells less dependent on oxygen. The molecular basis for physiological and pathological regulation of glucose metabolism is beginning to emerge with the identification of transcription factors that regulate glycolytic genes (2).

The ability of c-Myc, USF1, and HIF-1 transcription factors to regulate the LDH-A promoter through a Myc consensus binding site 5'-CACGTG-3' suggests that these transcription factors converge onto common cis elements (5'-RCGTG-3') that are found in regulatory sequences of glycolytic genes (20). Because hypoxia physiologically induces glycolytic gene expression through HIF-1 binding sites, it stands to reason that glycolysis might also be activated by USF or c-Myc. Hence, we sought to determine whether c-Myc regulates genes that are also regulated by HIF-1.

In this study, we observe that the glucose transporter GLUT1, PFK, GAPDH, GPI, PGM, and enolase are up-regulated by c-Myc in fibroblasts. In addition, we used adenovirus-mediated gene transfer to the liver as a means of studying in vivo gene expression and determined that these genes are also up-regulated by c-Myc in vivo. Our findings agree with a previous study of transgenic mice that also suggests the in vivo regulation of hepatic glycolysis by c-myc (41), although GLUT2, but not GLUT1, was induced in the transgenic livers. While our observation supports the hypothesis that c-Myc induces GLUT1 expression in the liver in vivo, the physiological significance of this induction is unclear because GLUT2 is the dominant form of hepatic glucose transporter. The use of transgenic mice, however, cannot establish whether c-Myc regulates certain genes directly. In our study, only GLUT1, PFK, and enolase behave as direct target genes in the MycER system. While some HIF-1 and c-Myc target genes overlap, the two sets of targets remain distinct. For example, the mRNA levels for HKI and adolase are unchanged or decreased by c-Myc, but are hypoxia inducible (2, 13, 14). GPI is increased by c-Myc but is unaffected by hypoxia. Furthermore, we have reported that c-Myc overexpression down-regulates VEGF, a HIF-1-mediated hypoxia-inducible gene (42).

We observed that c-Myc directly induces GLUT1 and increases glucose uptake in the Rat1 MycER cells. In addition to LDH-A, GLUT1 is an intriguing c-Myc target when its role in oncogenesis is considered (37, 38). Elevation of GLUT1 and c-Myc RNA are among the earliest changes in gene expression after Ha-ras T24 transformation of Rat1a fibroblasts (39). Reduction of GLUT1 expression through antisense GLUT1 RNA suppresses NIH 3T3 cell transformation by N-ras (40). Hence, the induction of GLUT1 expression by c-Myc may play an important role in tumor glucose metabolism.

The specific roles of PFK and enolase in tumorigenesis are less clear. Glycolytic flux is controlled at multiple steps of glycolysis, such that interruption of a non-rate-limiting step may affect overall flux (43). PFK is a rate-limiting glycolytic enzyme due to its intricate allosteric responses to ATP/ADP ratios and therefore may be critically important for the control of glycolytic flux. Enolase has not been directly implicated in human cancers; however, it is intriguing to note that a negative transactivating factor of the c-myc promoter (myc-binding protein 1) may be identical to enolase A (44, 45). While the role for enolase in regulating c-myc expression remains to be confirmed and further studied, this finding suggests that the induction of enolase by c-Myc may increase glycolysis and also serves as a negative feedback onto c-myc gene expression.

In summary, we observe that while both c-Myc and HIF-1 up-regulates GLUT1 and glycolytic gene expression, the sets of target genes for these transcription factors are distinct. HIF-1 physiologically induces glycolytic gene expression in hypoxic cells that also undergo growth arrest. By contrast, c-Myc stimulates glucose uptake, glycolysis, and overall metabolism as well as activates the cell cycle machinery, which are all necessary for cell proliferation (46). The widespread deregulation of the c-myc gene in human cancers, therefore, may be a major contributor to the enhanced tumor glycolysis known as the Warburg effect, which may confer growth advantage to tumor cells deprived of oxygen.

	ACKNOWLEDGEMENTS

We thank Dr. G. L. Semenza for IMAGE Consortium glycolytic enzyme cDNA clones, Dr. W. El-Deiry for adenoviruses, and Dr. L. Gardner for comments.

	FOOTNOTES

^* This work was supported by the Alexander and Margaret Stewart Trust Fund, a research grant from the Maryland American Cancer Society, and National Institutes of Health Grant CA 51497.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

^¶ Special fellow of the Leukemia Society of America.

Fellow of the Lymphoma Research Foundation of America.

^** To whom correspondence should be addressed: Ross Research Building, Room 1025, The Johns Hopkins University School of Medicine, 720 Rutland Ave., Baltimore, MD 21205. Tel.: 410-955-2773; Fax: 410-955-0185; E-mail: cvdang@jhmi.edu.

Fellow of the Lymphoma Research Foundation of America.

Published, JBC Papers in Press, May 22, 2000, DOI 10.1074/jbc.C000023200

² S. Kim, Q. Li, C. V. Dang, and A. Lee, unpublished observations.

	ABBREVIATIONS

The abbreviations used are: ChoRE, carbohydrate response element; HIF, hypoxia-inducible transcription factor; GLUT1, glucose transporter 1; LDH, lactate dehydrogenase; DMEM, Dulbecco's modified Eagle's medium; FBS, fetal bovine serum; MLV, murine leukemia virus; HOTM, hydroxytamoxifen; TM, tamoxifen; CHX, cycloheximide; 2-DG, 2-deoxyglucose; PFK, phosphofructokinase; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GPI, phosphoglucose isomerase; PGM, phosphoglycerate mutase; TPI, triose-phosphate isomerase; HK, hexokinase.

	REFERENCES

TOP ABSTRACT INTRODUCTION EXPERIMENTAL PROCEDURES RESULTS DISCUSSION REFERENCES

CiteULike

Complore

Connotea

Del.icio.us

Digg

Reddit

Technorati

This article has been cited by other articles:

				R. J. Gillies, I. Robey, and R. A. Gatenby Causes and Consequences of Increased Glucose Metabolism of Cancers J. Nucl. Med., June 1, 2008; 49(Suppl_2): 24S - 42S. [Abstract] [Full Text] [PDF]

				P. T. Winnard Jr., A. P. Pathak, S. Dhara, S. Y. Cho, V. Raman, and M. G. Pomper Molecular Imaging of Metastatic Potential J. Nucl. Med., June 1, 2008; 49(Suppl_2): 96S - 112S. [Abstract] [Full Text] [PDF]

				B. Clem, S. Telang, A. Clem, A. Yalcin, J. Meier, A. Simmons, M. A. Rasku, S. Arumugam, W. L. Dean, J. Eaton, et al. Small-molecule inhibition of 6-phosphofructo-2-kinase activity suppresses glycolytic flux and tumor growth Mol. Cancer Ther., January 1, 2008; 7(1): 110 - 120. [Abstract] [Full Text] [PDF]

				J.-w. Kim, P. Gao, Y.-C. Liu, G. L. Semenza, and C. V. Dang Hypoxia-Inducible Factor 1 and Dysregulated c-Myc Cooperatively Induce Vascular Endothelial Growth Factor and Metabolic Switches Hexokinase 2 and Pyruvate Dehydrogenase Kinase 1 Mol. Cell. Biol., November 1, 2007; 27(21): 7381 - 7393. [Abstract] [Full Text] [PDF]

				V. B. Sampson, N. H. Rong, J. Han, Q. Yang, V. Aris, P. Soteropoulos, N. J. Petrelli, S. P. Dunn, and L. J. Krueger MicroRNA Let-7a Down-regulates MYC and Reverts MYC-Induced Growth in Burkitt Lymphoma Cells Cancer Res., October 15, 2007; 67(20): 9762 - 9770. [Abstract] [Full Text] [PDF]

				M. Yuneva, N. Zamboni, P. Oefner, R. Sachidanandam, and Y. Lazebnik Deficiency in glutamine but not glucose induces MYC-dependent apoptosis in human cells J. Cell Biol., October 3, 2007; 178(1): 93 - 105. [Abstract] [Full Text] [PDF]

				F. Lopez-Rios, M. Sanchez-Arago, E. Garcia-Garcia, A. D. Ortega, J. R. Berrendero, F. Pozo-Rodriguez, A. Lopez-Encuentra, C. Ballestin, and J. M. Cuezva Loss of the Mitochondrial Bioenergetic Capacity Underlies the Glucose Avidity of Carcinomas Cancer Res., October 1, 2007; 67(19): 9013 - 9017. [Abstract] [Full Text] [PDF]

				I. Serganova, J. Humm, C. Ling, and R. Blasberg Tumor hypoxia imaging. Clin. Cancer Res., September 15, 2006; 12(18): 5260 - 5264. [Full Text] [PDF]

				C. L. Sans, D. J. Satterwhite, C. A. Stoltzman, K. T. Breen, and D. E. Ayer MondoA-Mlx Heterodimers Are Candidate Sensors of Cellular Energy Status: Mitochondrial Localization and Direct Regulation of Glycolysis. Mol. Cell. Biol., July 1, 2006; 26(13): 4863 - 4871. [Abstract] [Full Text] [PDF]

				C. A. Doughty, B. F. Bleiman, D. J. Wagner, F. J. Dufort, J. M. Mataraza, M. F. Roberts, and T. C. Chiles Antigen receptor-mediated changes in glucose metabolism in B lymphocytes: role of phosphatidylinositol 3-kinase signaling in the glycolytic control of growth Blood, June 1, 2006; 107(11): 4458 - 4465. [Abstract] [Full Text] [PDF]

				D.-Y. Hwang and F. Ismail-Beigi Control of Glut1 promoter activity under basal conditions and in response to hyperosmolarity: role of Sp1 Am J Physiol Cell Physiol, February 1, 2006; 290(2): C337 - C344. [Abstract] [Full Text] [PDF]

				A. Isidoro, E. Casado, A. Redondo, P. Acebo, E. Espinosa, A. M. Alonso, P. Cejas, D. Hardisson, J. A. Fresno Vara, C. Belda-Iniesta, et al. Breast carcinomas fulfill the Warburg hypothesis and provide metabolic markers of cancer prognosis Carcinogenesis, December 1, 2005; 26(12): 2095 - 2104. [Abstract] [Full Text] [PDF]

				J. B. Fleming, G.-L. Shen, S. E. Holloway, M. Davis, and R. A. Brekken Molecular Consequences of Silencing Mutant K-ras in Pancreatic Cancer Cells: Justification for K-ras-Directed Therapy Mol. Cancer Res., July 1, 2005; 3(7): 413 - 423. [Abstract] [Full Text] [PDF]

				M. Tsuneoka, K. Teye, N. Arima, M. Soejima, H. Otera, K. Ohashi, Y. Koga, H. Fujita, K. Shirouzu, H. Kimura, et al. A Novel Myc-target Gene, mimitin, That Is Involved in Cell Proliferation of Esophageal Squamous Cell Carcinoma J. Biol. Chem., May 20, 2005; 280(20): 19977 - 19985. [Abstract] [Full Text] [PDF]

				G. J. Kelloff, J. M. Hoffman, B. Johnson, H. I. Scher, B. A. Siegel, E. Y. Cheng, B. D. Cheson, J. O'Shaughnessy, K. Z. Guyton, D. A. Mankoff, et al. Progress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development Clin. Cancer Res., April 15, 2005; 11(8): 2785 - 2808. [Abstract] [Full Text] [PDF]

				A. Mayer, M. Hockel, A. Wree, and P. Vaupel Microregional Expression of Glucose Transporter-1 and Oxygenation Status: Lack of Correlation in Locally Advanced Cervical Cancers Clin. Cancer Res., April 1, 2005; 11(7): 2768 - 2773. [Abstract] [Full Text] [PDF]

				Y. Mizukami, A. Iwamatsu, T. Aki, M. Kimura, K. Nakamura, T. Nao, T. Okusa, M. Matsuzaki, K.-i. Yoshida, and S. Kobayashi ERK1/2 Regulates Intracellular ATP Levels through {alpha}-Enolase Expression in Cardiomyocytes Exposed to Ischemic Hypoxia and Reoxygenation J. Biol. Chem., November 26, 2004; 279(48): 50120 - 50131. [Abstract] [Full Text] [PDF]

				S. Tsutsumi, T. Yanagawa, T. Shimura, H. Kuwano, and A. Raz Autocrine Motility Factor Signaling Enhances Pancreatic Cancer Metastasis Clin. Cancer Res., November 15, 2004; 10(22): 7775 - 7784. [Abstract] [Full Text] [PDF]

				J.-w. Kim, K. I. Zeller, Y. Wang, A. G. Jegga, B. J. Aronow, K. A. O'Donnell, and C. V. Dang Evaluation of Myc E-Box Phylogenetic Footprints in Glycolytic Genes by Chromatin Immunoprecipitation Assays Mol. Cell. Biol., July 1, 2004; 24(13): 5923 - 5936. [Abstract] [Full Text] [PDF]

				T. Doedt, S. Krishnamurthy, D. P. Bockmuhl, B. Tebarth, C. Stempel, C. L. Russell, A. J.P. Brown, and J. F. Ernst APSES Proteins Regulate Morphogenesis and Metabolism in Candida albicans Mol. Biol. Cell, July 1, 2004; 15(7): 3167 - 3180. [Abstract] [Full Text] [PDF]

				R. L. Elstrom, D. E. Bauer, M. Buzzai, R. Karnauskas, M. H. Harris, D. R. Plas, H. Zhuang, R. M. Cinalli, A. Alavi, C. M. Rudin, et al. Akt Stimulates Aerobic Glycolysis in Cancer Cells Cancer Res., June 1, 2004; 64(11): 3892 - 3899. [Abstract] [Full Text] [PDF]

				S. Tsutsumi, T. Yanagawa, T. Shimura, T. Fukumori, V. Hogan, H. Kuwano, and A. Raz Regulation of Cell Proliferation by Autocrine Motility Factor/Phosphoglucose Isomerase Signaling J. Biol. Chem., August 22, 2003; 278(34): 32165 - 32172. [Abstract] [Full Text] [PDF]

				S. Singhal, R. Wiewrodt, L. D. Malden, K. M. Amin, K. Matzie, J. Friedberg, J. C. Kucharczuk, L. A. Litzky, S. W. Johnson, L. R. Kaiser, et al. Gene Expression Profiling of Malignant Mesothelioma Clin. Cancer Res., August 1, 2003; 9(8): 3080 - 3097. [Abstract] [Full Text] [PDF]

				E. Janssen, A. de Groof, M. Wijers, J. Fransen, P. P. Dzeja, A. Terzic, and B. Wieringa Adenylate Kinase 1 Deficiency Induces Molecular and Structural Adaptations to Support Muscle Energy Metabolism J. Biol. Chem., April 4, 2003; 278(15): 12937 - 12945. [Abstract] [Full Text] [PDF]

B. C. O'Connell, A. F. Cheung, C. P. Simkevich, W. Tam, X. Ren, M. K. Mateyak, and J. M. Sedivy A Large Scale Genetic Analysis of c-Myc-regulated Gene Expression Patterns<